폐암 (NSCLC)

161개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved161 programs
CGTLimited DatastaleGuangzhou Yiyang Biological Tec…Phase 1

CAR-T cells to treat advanced lung cancer (CAR-T cells to treat advanced lung cancer)

Advanced Lung Cancer · Advanced Lung Cancer

#AdvancedLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

CAR-T combining PD-1 Knockout (CAR-T combining PD-1 Knockout)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleGerman Cancer Research CenterPhase 2

CC-1 and Toczilizumab (CC-1 and Toczilizumab)

Lung Cancer Squamous Cell · Lung Cancer Squamous Cell

#LungCancerSquamousCell#Antibody#Phase2#monoclonal-antibody#German
Trials 1Status Discontinued
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

CEA CAR-T cells (CEA CAR-T cells)

Solid Tumor; Lung Cancer · CEA

#CEA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Intrapleural (CEA-targeted CAR-T, CEA-targeted CAR-T (Intrapleural))

NSCLC (Advanced Non-small Cell Lung Cancer); Breast Cancer · CEA

#CEA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Intravenous (CEA-targeted CAR-T, CEA-targeted CAR-T (Intravenous))

NSCLC (Advanced Non-small Cell Lung Cancer); Breast Cancer · CEA

#CEA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleCorvus Pharmaceuticals, Inc.Phase 1

pembrolizumab (Keytruda, CPI-006 + pembrolizumab)

Non-Small Cell Lung Cancer; Renal Cell Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase1#monoclonal-antibody#RenalCellCancer+1
Trials 1Status Active
AntibodyLimited DatastaleIdris BahceApproved

durvalumab (Imfinzi, Consolidation durvalumab)

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage III

#Non-smallCellLungCancerStageIII#Antibody#Approved#monoclonal-antibody#Idris
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity of Texas Southwester…Phase 2

durvalumab (Imfinzi, Consolidative Durvalumab)

Non Small Cell Lung Cancer; Lung Cancer Stage III · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#LungCancerStageIII+1
Trials 1Status Active
AntibodyLimited DatastaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Dizal
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin + tislelizumab + bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
AntibodyLimited DatastaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#monoclonal-antibody#AdvancedorMetastaticNon-Small-Ce+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital of G…Phase 1

EGFR/B7H3 CAR-T (EGFR/B7H3 CAR-T)

EGFR/ B7H3-positive Advanced Lung Cancer; EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleBrightPath BiotherapeuticsPhase 2

pembrolizumab (Keytruda, GRN-1201 + Pembrolizumab)

Metastatic NSCLC · Metastatic NSCLC

#MetastaticNSCLC#Antibody#Phase2#monoclonal-antibody#BrightPath
Trials 1Status Discontinued
AntibodyLimited DatastaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Hunan
Trials 1Status Active
AntibodyLimited DatastaleShanghai Pulmonary Hospital, Sh…Phase 2

IBI310+Sintilimab (IBI310+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Shanghai
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab plus guadecitabine)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#NonSmallCellLungCancer+1
Trials 1Status Active

5 / 9 pages

← PreviousNext →